1 – 5 of 10
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS : Results from the nordic NMDSG08A phase II trial
(
- Contribution to journal › Article
- 2011
-
Mark
Quality of life, physical function and MRI T2*in elderly low-risk MDS patients treated to a haemoglobin level of >= 120 g/L with darbepoetin alfa +/- filgrastim or erythrocyte transfusions
(
- Contribution to journal › Article
- 2009
-
Mark
Expression of p53 or cytoplasmic nucleophosmine associated with increased risk of disease progression in myelodysplastic syndrome with isolated del(5q)
(
- Contribution to journal › Published meeting abstract
-
Mark
Expression of P53 or cytoplasmic nucleophosmine associated with increased risk of disease progression in myelodysplastic syndrome with isolated del(5Q)
2009) 14th Annual Meeting of the European-Hematology-Association In Haematologica-The Hematology Journal 94. p.0257-0257(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells
(
- Contribution to journal › Article